Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » Webinar: ADC’s are back stronger than ever: how, why & what’s next

Webinar: ADC’s are Back Stronger Than Ever: How, Why & What’s Next

Summary: Antibody-drug conjugates (ADCs) have achieved commercial success over the last ten years. ADCs offer the prospect of more precise treatments and a reduction in off-target effects, however challenges including instability remain. In this on-demand presentation, Mike Riley, President, Catalent Biologics, will discuss the latest trends in ADC discovery and development, with a focus on how next generation pipelines are being shaped by payload and linker chemistry innovations, including those from Catalent’s award-winning SMARTag® ADC platform.

Click here to view the webinar